Financials data is unavailable for this security.
View more
Year on year Cipla Ltd grew revenues 13.28% from 227.53bn to 257.74bn while net income improved 47.10% from 28.02bn to 41.22bn.
| Gross margin | 66.43% |
|---|---|
| Net profit margin | 16.58% |
| Operating margin | 20.12% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Cipla Ltd fell by 489.90m. However, the company earned 41.34bn from its operations for a Cash Flow Margin of 16.04%. In addition the company used 29.88bn on investing activities and also paid 12.00bn in financing cash flows.
| Cash flow per share | 66.77 |
|---|---|
| Price/Cash flow per share | 24.73 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 52.94% and 47.16%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.73% |
|---|---|
| Div growth rate (5 year) | 34.08% |
| Payout ratio (TTM) | 24.39% |
| EPS growth(5 years) | 21.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 38.25 |
More ▼
